Lea Eslava-Kim, PharmD

Drug Information Specialist https://www.neurologyadvisor.com

Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.

All articles by Lea Eslava-Kim, PharmD

man in pain parkinson's

Movement Disorders

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

By

Lea Eslava-Kim, PharmD

January 9, 2017

The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

FDA Fast Tracks Potential Neuropathy Treatment

By

Lea Eslava-Kim, PharmD

September 27, 2016

The designation has been granted to potentially treat neuropathic pain associated with diabetic peripheral neuropathy.

General Neurology

OV101 Wins Orphan Drug Status for Rare Neurological Disorder

By

Lea Eslava-Kim, PharmD

September 13, 2016

The treatment is currently being investigated in a Phase 2 trial in adults with Angelman syndrome

Pain

FDA Accepts NDA for Controlled Opioid Agonist

By

Lea Eslava-Kim, PharmD

March 3, 2016

The FDA has accepted an NDA for Arymo ER (morphine sulfate; Egalet) extended-release tablets.

Neuromuscular Disorders

NDA Submitted for Duchenne Muscular Dystrophy Drug

By

Lea Eslava-Kim, PharmD

January 8, 2016

Translarna (ataluren) is for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

Neurodegenerative Diseases

Novel Huntington’s Treatment Wins Orphan Drug Status

By

Lea Eslava-Kim, PharmD

January 13, 2016

The FDA has granted Orphan Drug designation to IONIS-HTT (Ionis) for the treatment of Huntington’s disease.

Next post in Neurodegenerative Diseases

Dementia Risk Elevated in Patients with Type 2 Diabetes